After establishing that vaccination provided significant breaking of humoral tolerance and offered tumor-free survival against CEA-expressing tumors, we next tested whether the anti-tumor effect of rAAV-CEA vaccination was antigen-specific, using the parental version of MC38-CEA cells that lack CEA expression (MC38). The gene discussed is CEACAM5; the disease is neoplasm.